Notices. Notice
192 words·~1 min read·
/register/2019/08/21/2019-18026·A research copy — for the controlling text, always check the official state or federal source. Not legal advice.
BILLING CODE 4164-01-P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA-2019-N-2396] Psychopharmacologic Drugs Advisory Committee; Cancellation AGENCY: Food and Drug Administration, HHS. ACTION: Notice. SUMMARY: The meeting of the Psychopharmacologic Drugs Advisory Committee scheduled for July 31, 2019, has been canceled. This meeting was announced in the **Federal Register** of June 14, 2019. This meeting has been canceled because of new information regarding the application.
The Agency intends to continue evaluating the application and, as needed, will announce future meeting dates in the **Federal Register** . FOR FURTHER INFORMATION CONTACT: Jay Fajiculay, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 31, Rm. 2417, Silver Spring, MD 20993-0002, 301-796-9001, Fax: 301-847-8533, email: *PDAC@fda.hhs.gov,* or FDA Advisory Committee Information Line, 1-800-741-8138 (301-443-0572 in the Washington, DC area), and follow the prompts to the desired center or product area.
Please call the Information Line for up-to-date information on this meeting, which was announced in the **Federal Register** of June 14, 2019 (84 FR 27783). Dated: August 16, 2019. Lowell J. Schiller, Principal Associate Commissioner for Policy. [FR Doc. 2019-18026 Filed 8-20-19; 8:45 am]